These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 35138572

  • 1. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T, Inagaki N, Watada H, Sasaki K, Mori-Anai K, Iwasaki T, Teranishi T.
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T, Haneda M, Ito H, Sasaki K, Matsukawa M, Yamada Y.
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Watanabe Y, Gouda M, Iijima H.
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Iijima H, Watanabe Y, Gouda M.
    Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y.
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
    Kadowaki T, Haneda M, Ito H, Ueno M, Matsukawa M, Yamakura T, Sasaki K, Kimura M, Iijima H.
    Expert Opin Pharmacother; 2018 Feb; 19(2):83-91. PubMed ID: 29268035
    [Abstract] [Full Text] [Related]

  • 12. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y, Usami M, Inoue T.
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [Abstract] [Full Text] [Related]

  • 13. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
    Son C, Makino H, Kasahara M, Tanaka T, Nishimura K, Taneda S, Nishimura T, Kasama S, Ogawa Y, Miyamoto Y, Hosoda K.
    Diabetes Res Clin Pract; 2021 Oct; 180():109037. PubMed ID: 34481910
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T, Kondo K.
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, Ikenaga Y, Nakamaru Y, Hikida K, Saito A, Arakawa K, Oka K, Ueta K, Shiotani M.
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [Abstract] [Full Text] [Related]

  • 20. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H.
    J Diabetes Investig; 2021 Aug; 12(8):1395-1399. PubMed ID: 33325645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.